# Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPE

> **NCT04688320** · PHASE3 · COMPLETED · sponsor: **Supergene, LLC** · enrollment: 310 (actual)

## Conditions studied

- Massive Pulmonary Embolism

## Interventions

- **DRUG:** Recombinant nonimmunogenic staphylokinase
- **DRUG:** Alteplase

## Key facts

- **NCT ID:** NCT04688320
- **Lead sponsor:** Supergene, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-15
- **Primary completion:** 2023-07-27
- **Final completion:** 2023-07-27
- **Target enrollment:** 310 (ACTUAL)
- **Last updated:** 2025-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04688320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04688320, "Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPE". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04688320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*